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Transdermal scopolamine may be used to reduce drooling in
children with disabilities. Side-effects include dilated pupils
and a reduction in the near point of accommodation (the
closest point at which clear vision is possible). Two male
children with epilepsy, one with spinal dysraphism (aged 7y
6mo) and one with cerebral palsy (aged 5y 8mo), who have
undergone treatment for drooling with transdermal
scopolamine are described. Near visual acuity was reduced,
and both children showed dilated pupils with reduced or no
response to light. These responses became normal on
cessation of the scopolamine patch. As the effect of this drug
may be cumulative, and many patients are unable to
communicate difficulties, clinicians need to be aware of these
possible side-effects.
The significant reduction of salivary flow by the administr-
tation of transdermal scopolamine has led to its use for
drooling (sialorrhea). With repeated doses of the drug, visu-
al problems, including a reduction in the near point of acco-
mmodation (the closest point at which clear vision is possi-
ble), have been reported in adults without disabilities (Parrott
1986). No mydriasis (dilation of the pupil) or other side-
effects were observed by Siegel and Klingbeil (1991) in a 4-year-
old child with severe spastic quadriplegia, developmental
delay, and extremely limited cognitive function who used
scopoderm over a 2-year period – a new patch being applied
every 72 hours. However, when investigating short-term wear
in children with developmental delay aged 5 to 18 years, two-
thirds of the patients were noted to have pupillary dilation
(Lewis et al. 1994). 
We report two chidren who appeared to have near vision
problems when using transdermal scopolamine (Scopoderm
TTS) patches which dispense 1mg of the drug over a 72-hour
period.
Child 1
A male aged 7 years 6 months with spinal dysraphism and
epilepsy was seen during routine vision screening in his
school. Generally, he had moderate delay and severe commu-
nication problems. His mother reported that the child was sen-
sitive to light even when wearing a hat. Distance visual acuity
was 6/6 in either eye, and near visual acuity was 6/15 (Lea sym-
bols) with both eyes open. Pupils were both dilated and unre-
active. Subjective response to accommodation testing was not
possible due to reduced level of cooperation. No strabismus
was present and there was no need for glasses (refractive error
was right [R]:+0.50 and left [L]:+0.50/-0.50 at 180). However,
sunglasses were advised. A full scopolamine patch was being
worn, and sodium valproate (400mg) taken twice daily. After
discussion with the paediatrician the patch was left off. Near
visual acuity improved to 6/7.5 (Cardiff cards) with both eyes
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open. Pupillary responses were normal. The teacher reported
that the child’s attention had improved. 
Child 2
A male with cerebral palsy (CP), microcephaly, epilepsy, and
global developmental delay had been under observation and
was wearing glasses for long sightedness (R:+5.00/+1.00 at
90 and L:+5.00/+0.50 at 90). Pupils had been noted to react
directly to light, but when seen at the age of 5 years 8 months
pupils were dilated and not constricting fully to light. He
was taking clobazam 2mg twice daily in liquid form and
wearing a scopolamine patch. The patch had been increased
from a quarter to a full patch by his mother because he was
still drooling. Formal testing was limited because the child
had severe learning difficulties and no means of communica-
tion. An intermittent convergent squint was queried and
visual acuity tested at 0.5m (Cardiff cards) was 6/76 with
both eyes open when the patch was being worn and 6/48
when he was seen without the patch. 
Discussion
Both children showed reduced near vision at the time when
the scopolamine patch was being worn. This would be a con-
sistent finding if accommodation was reduced, however for-
mal testing of this was not possible in either male due to lack of
cooperation. The lack of cooperation could also affect the
repeatability of the visual acuity tests. Child 1 performed a test
which demanded cooperation and reduced near vision (tested
at 33cm) was found in relation to distance vision (tested at 6m)
while wearing the patch. As concentration is often easier to
maintain when using near tests we feel this is reliable. In child
2, only a near objective test was possible and cooperation
could have affected repeatability.
Dilated pupils may also lead to blurred vision, increased
sensitivity to light, and other problems, such as increased flick-
er when viewing a computer screen. Brodtkorb et al. (1988)
point out that the identification of side-effects is difficult in
patients who have little or no speech. If a near vision problem is
identified which is due to reduced accommodation, lenses
may be prescribed for near work or a bifocal segment given if
glasses are already worn. However, this necessitates the child
looking through the correct part of the glasses and bifocal use
can be difficult in a child with multiple disabilities.
Good and Crain (1996) report a case of a 4-year-old male
with spastic quadriplegia prescribed one-quarter of a patch.
After 5 days a 40 prism dioptre convergent strabismus
(inward turning eye) developed, no significant hyperme-
tropia (long sightedness) was present, and pupils were round
and reactive to light. Seven days after cessation of the patch,
the deviation had resolved. The authors suggest that the
effect on accommodation led to the strabismus. 
After a study on the short-term safety of use in children (aged
1–11y) where scopolamine has been used prophylactically as
an anti-emetic after strabismus surgery, Horimoto et al.
(1991) state that the size of the existing patches should be
reduced for children. In their study a quarter patch was used
for children under 2 years old, and one-half in older chil-
dren. Serum levels of this drug may be increased following
successive patch applications (Schmitt et al. 1981).
Accommodation has been shown to be reduced in patients
with CP(Leat 1996) and this may be an additional factor in
resultant near vision problems in these children. The side-
effects of other medication may also affect the near response,
but in our cases improvement was shown on cessation of the
patch.
Alternative forms of treatment for drooling are available,
including behavioural approaches. Other medications avail-
able are also antimuscarinic and so have potentially similar
side-effects. Where medication is unsuccessful, or side-effects
are severe, intraglandular botulinum toxin or surgery may be
considered (Blasco 2002).
Clinicians need to be alert to the problems with near vision
that may result from the use of scopolamine for drooling in
children with disabilities.
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